Stay updated on T-DXd Combos in HER2+ MBC Clinical Trial
Sign up to get notified when there's something new on the T-DXd Combos in HER2+ MBC Clinical Trial page.

Latest updates to the T-DXd Combos in HER2+ MBC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe webpage has been updated to reflect a new study involving Pertuzumab and Tucatinib for HER2-positive metastatic breast cancer, replacing the previous focus on trastuzumab deruxtecan. Key details about the study's phases and patient enrollment criteria have been clarified.SummaryDifference21%
- Check20 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 14, 2025.SummaryDifference0.3%
- Check28 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of February 14, 2025, and version 2.14.2.SummaryDifference0.2%
- Check57 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check71 days agoChange DetectedThe webpage has updated its date references, removing several past dates and adding new future dates, indicating a shift in the timeline of events or updates.SummaryDifference0.8%
- Check78 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to T-DXd Combos in HER2+ MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DXd Combos in HER2+ MBC Clinical Trial page.